Search for dissertations about: "SLCO1B1"

Found 4 swedish dissertations containing the word SLCO1B1.

  1. 1. In vitro and in silico prediction of drug-drug interactions with transport proteins

    University dissertation from Uppsala : Acta Universitatis Upsaliensis

    Author : Gustav Ahlin; Uppsala universitet.; [2009]
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Solute carrier; SLC transporter; OCT1; Organic cation transporter 1; SLC22A1; OATP1B1; SLCO1B1; Organic anion transporting peptide 1B1; Drug transport; Active transport; Genetic polymorphism; Cell lines; Gene expression; Multivariate data analysis; OPLS; PHARMACY Pharmaceutics; FARMACI Galenisk farmaci; PHARMACY Biopharmacy; FARMACI Biofarmaci; galenisk farmaci; Pharmaceutics; Biopharmaceutics; biofarmaci;

    Abstract : Drug transport across cells and cell membranes in the human body is crucial for the pharmacological effect of drugs. Active transport governed by transport proteins plays an important role in this process. A vast number of transport proteins with a wide tissue distribution have been identified during the last 15 years. READ MORE

  2. 2. Incidence, predictors and biomarkers for antiretroviral and/or anti-tuberculosis drugs induced liver injury

    University dissertation from Stockholm : Karolinska Institutet, Dept of Laboratory Medicine

    Author : Getnet Yimer Ali; Karolinska Institutet.; Karolinska Institutet.; [2012]
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES;

    Abstract : Anti-tuberculosis and/or antiretroviral drugs induced liver injury (DILI) is a major challenge when managing TB and/or HIV patients. The aims of this thesis were to identify incidence, risk factors, and management of DILI among 4 different treatment groups namely; HIV positive individuals with no TB co-infection and had a CD4 count of < 200 cells/μl (taking ARV drugs alone = arm 1), TB-HIV co-infected patients with a CD4 count of < 200 cells/μl (taking both anti-TB and ARV drugs = arm 2), TB-HIV coinfected patients with a CD4 count of > 200 cells/μl (taking anti-TB alone = arm 3), HIV negative TB patients (taking anti-TB alone = arm 4). READ MORE

  3. 3. Pharmacokinetic and Pharmacogenetic aspects of drug-drug interactions between antiretroviral and anti-tuberculosis drugs in Ethiopian patients: Implication for optimization of TB-HIV co-treatment

    University dissertation from Stockholm : Karolinska Institutet, Dept of Laboratory Medicine

    Author : Abiy Habtewolde Eyakem; Karolinska Institutet.; Karolinska Institutet.; [2013]
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES;

    Abstract : TB and HIV are immuno-pathologically interacting epidemic infectious diseases affecting the lives of millions globally & sub-Saharan African region accounts the highest burden of both diseases. Although effective therapies are available for the management of each, TB-HIV co-treatment has faced challenges mainly due to drug-drug interactions & overlapping drug toxicities. READ MORE

  4. 4. Optimization of HIV and tuberculosis co-treatment in Tanzania : drug-drug interactions and clinical outcomes

    University dissertation from Stockholm : Karolinska Institutet, Dept of Clinical Science and Education, Södersjukhuset

    Author : Sabina Mugusi; Karolinska Institutet.; Karolinska Institutet.; [2013]
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; HIV;

    Abstract : Background: Sub-Saharan Africa has been greatly affected by the HIV epidemic, with an estimated 23.5 million people living with HIV/AIDS (PLWHA) residing within this region by the end of 2011, being the leading course of morbidity and mortality. Tanzania is one of the countries in this region with an HIV prevalence of 5.7% i. READ MORE